Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | ATR | Q13535 | 2/20 | 0.35 |
| ▸ | RET | P07949 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | PDE8B | O95263 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25698640 | 0.87 | PDE4B (0.39) | CYP4F2CYP4A11PDE4BPDE7AGAA | |
| SCHEMBL24322361 | 0.84 | PDE4B (0.37) | CYP4F2CYP4A11PDE4BPDE7AGAA | |
| SCHEMBL24322191 | 0.81 | CYP4F2 (0.36) | CYP4F2CYP4A11PDE4BPDE7AGAA | |
| SCHEMBL24322976 | 0.80 | CYP4F2 (0.37) | CYP4F2CYP4A11PDE4BPDE7AGAA | |
| SCHEMBL24322977 | 0.76 | GAA (0.43) | CYP4F2CYP4A11PDE4BPDE7AGAA | |
| SCHEMBL24322359 | 0.72 | RET (0.37) | CYP4F2CYP4A11PDE4BPDE7AGAA | |
| SCHEMBL24497787 | 0.72 | CYP4F2 (0.48) | CYP4F2CYP4A11GAACYP2C19ATR | |
| SCHEMBL24322176 | 0.71 | CYP4F2 (0.36) | CYP4F2CYP4A11PDE4BPDE7AGAA | |
| SCHEMBL31206437 | 0.69 | CYP4F2 (0.39) | CYP4F2CYP4A11GAACYP2C19ATR | |
| SCHEMBL17377535 | 0.68 | GAA (0.44) | CYP4F2CYP4A11GAACYP2C19ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | CYP4F2 1763/4885CYP4A11 1132/4885PDE4B 1545/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | CYP4F2 1763/4885CYP4A11 1132/4885PDE4B 1545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.